Novocure Ltd (NVCR)

Novocure Ltd (NVCR) is a NASDAQ-listed healthcare equipment and supplies company, and the security context here is common equity. The listing represents ordinary shares in Novocure Ltd rather than a fund, debt instrument, or other special security. Based on its business classification, the company is associated with device-based cancer care and related medical technology activities. The shares trade on NASDAQ under the symbol NVCR and should be understood as an equity interest in the issuer. This overview describes the security type and market listing, not a recommendation or a forecast about its prospects.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-NVCR
$19.65
17.9% Upside
Fair
$27.14
62.8% Upside
Bargain
Good
0.0%
October 22, 2026
5.7x
2.8x
1.941 B
1.734 B
10.8%
82.8%
0.5
17.1%
Valuation • Fair Value

Novocure Ltd (NASDAQ-NVCR) Fair Value by Valuation Model

Review the available estimates for Novocure Ltd (NASDAQ-NVCR), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$19.65

Estimated upside of 17.9% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$25.56

Discounted cash flow valuation reference.

EPV Fair Value

$12.41

Earnings power value estimate.

Comps Fair Value

$18.88

Comparable-company valuation reference.

Analyst Price Target

$27.14

Analysts imply upside of 62.8%.

How to read these valuation models

Use the 6 available valuation references for Novocure Ltd (NASDAQ-NVCR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Novocure Ltd (NASDAQ-NVCR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

699.2 M

Current operating scale indicator.

Revenue Forecast

726.6 M

Forward revenue estimate.

EBITDA

-136.4 M

Current operating profitability reference.

EBITDA Forecast

-112.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Novocure Ltd (NASDAQ-NVCR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Novocure Ltd (NASDAQ-NVCR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Good

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-3.06

No elevated caution signal from this screen.

Altman Z-Score

0.5

Lower score that deserves closer risk review.

FCF / Net Income

17.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Novocure Ltd (NASDAQ-NVCR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Novocure Ltd (NASDAQ-NVCR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 22, 2026

Days to Earnings

30

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Novocure Ltd (NASDAQ-NVCR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Novocure Ltd (NASDAQ-NVCR) Stock Forecast & Technical Outlook

Review Novocure Ltd (NASDAQ-NVCR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Novocure Ltd (NASDAQ-NVCR) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Novocure Ltd (NASDAQ-NVCR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Novocure Ltd (NASDAQ-NVCR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Novocure Ltd (NASDAQ-NVCR) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Novocure Ltd (NASDAQ-NVCR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Novocure Ltd (NASDAQ-NVCR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Novocure Ltd (NASDAQ-NVCR) has a Buy consensus, with 3 buy, 3 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 3
Sell 0
FAQ Fast Investor Answers

Novocure Ltd (NASDAQ-NVCR) Stock FAQ

Data-supported answers about Novocure Ltd (NASDAQ-NVCR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$19.65
Estimated upside 17.9%
Valuation Rating
Undervalued
Estimated upside of 17.9%
Analyst Target
$27.14
Implied upside 62.8%
Financial Health
Good
Current financial-health read

The current fair value estimate for Novocure Ltd (NASDAQ-NVCR) is $19.65. This implies an estimated upside of 17.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 17.9% versus the current market price.

The available analyst price target for Novocure Ltd (NASDAQ-NVCR) is $27.14. The analyst target implies estimated upside of 62.8%.

The current financial health read for Novocure Ltd (NASDAQ-NVCR) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Novocure Ltd (NASDAQ-NVCR) is October 22, 2026.

The latest available data indicates no current dividend yield for Novocure Ltd (NASDAQ-NVCR).

The current market capitalization listed for Novocure Ltd is 1.941 B.

The current enterprise value listed for Novocure Ltd is 1.734 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Novocure Ltd is NASDAQ-NVCR, and the stock is listed on NASDAQ.

Novocure Ltd (NASDAQ-NVCR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Novocure Ltd is 10.8%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Novocure Ltd is 82.8%. Free float helps investors understand how much of the share base is available for public trading.